Merrimack Pharmaceuticals, Inc. Stock price

Equities

MACK

US5903282094

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
14.75 USD +0.20% Intraday chart for Merrimack Pharmaceuticals, Inc. +0.41% +9.99%
Sales 2022 - Sales 2023 - Capitalization 192M
Net income 2022 -1M Net income 2023 -1M EV / Sales 2022 -
Net cash position 2022 19.44M Net cash position 2023 18.88M EV / Sales 2023 -
P/E ratio 2022
-100 x
P/E ratio 2023
-162 x
Employees 27
Yield 2022 *
-
Yield 2023
-
Free-Float 98.79%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.20%
1 week+0.41%
Current month+0.34%
1 month+0.27%
3 months+10.90%
6 months+17.81%
Current year+9.99%
More quotes
1 week
14.72
Extreme 14.72
14.91
1 month
14.60
Extreme 14.6
14.91
Current year
12.94
Extreme 12.94
15.89
1 year
11.53
Extreme 11.53
15.89
3 years
3.00
Extreme 3
15.89
5 years
1.49
Extreme 1.49
15.89
10 years
1.49
Extreme 1.49
138.40
More quotes
Managers TitleAgeSince
Founder 52 92-12-31
Chief Executive Officer 72 03-12-31
Investor Relations Contact - -
Members of the board TitleAgeSince
Chief Executive Officer 72 03-12-31
Director/Board Member 45 19-09-18
Founder 52 92-12-31
More insiders
Date Price Change Volume
24-03-27 14.75 +0.20% 129,206
24-03-26 14.72 -0.07% 103,473
24-03-25 14.73 -0.41% 99,675
24-03-22 14.79 +0.68% 193,562
24-03-21 14.69 0.00% 90,378

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. The Company is entitled to receive contingent payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. Its payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of ONIVYDE for certain additional clinical indications. ONIVYDE is approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company's wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
  1. Stock
  2. Equities
  3. Stock Merrimack Pharmaceuticals, Inc. - Nasdaq